Supporting info on Statins usage |”Statin-Taking Patients With LDL-C of 70–100 mg/dL at Decreased Risk of MACE” #Update

As the controversies regarding the Statin usage grow day by day, Clalit Research Institute, Tel Aviv_Israel has done a population-based study of more than 31,000 statin-taking adults in Israel who had stable ischemic heart disease showed no significant differences in major adverse cardiac events (MACE) between those with LDL-C levels that were between 70 and 100 mg/dL after 1 year of treatment and those with LDL-C <70 mg/dL. However, there was a significantly lower risk for MACE in those with LDL-C of 70 to 100 mg/dL vs those with LDL-C levels of 100 to 130 mg/dL (P<0.001).

Although the European Society of Cardiology (ESC) currently recommends that long-term statin treatment for patients with CAD should target LDL-C levels less than 70 mg/dL, new research suggests that the optimal level is actually a bit higher

Read more about it here.


Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association